Kimmtrak

(Tebentafusp-tebn)

Kimmtrak

Drug updated on 1/26/2024

Dosage FormInjection (subcutaneous; 100 mcg/0.5 mL in a single-dose vial)
Drug ClassBispecific gp100 peptide-HLA-directed CD3 T cell engagers
Ongoing and Completed StudiesClinicalTrials.gov

Indication

  • For the treatment of HLA-A*02:01-positive adult patients with unresectable or metastatic uveal melanoma.

Product Monograph / Prescribing Information

Document TitleYearSource
Kimmtrak (tebentafusp-tebn) Prescribing Information.2022Immunocore Limited, Abingdon, United Kingdom

Systematic Reviews / Meta-Analyses